Viramal Appoints Experienced Pharmaceutical Executive, Angela Rossetti, to Board of Directors

150 150 Administrator

 Viramal Appoints Experienced Pharmaceutical Executive, Angela Rossetti, to Board of Directors

NEW YORK, May 18, 2016 /PRNewswire/ — Viramal, (“the Company”), an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, today announced the appointment of Angela Rossetti to its Board of Directors, effective immediately.

Ms. Rossetti is a highly qualified corporate director and pharmaceutical executive who brings more than 20 years’ industry experience to Viramal, including 10 years senior-level commercialization expertise at pharmaceutical and biotechnology companies. During the past decade she has been responsible for the commercialization of both mass market and rare disease franchises at Pfizer and Wyeth, and hemophilia products at an early stage biopharmaceutical company, Cell Machines.

Since 2015, Ms. Rossetti has been Executive Vice President and Chief Commercial Officer at Cell Machines, which is developing transformational technology for hemophilia and other diseases. From 2009 through 2012, she was a Vice President at Pfizer Inc., where she led a global commercial medicine team for smoking cessation products. Prior to that, she was an Assistant Vice President at Wyeth, managing a global hemophilia franchise from 2007 until 2009, when Wyeth was acquired by Pfizer.

“Angela Rossetti is a seasoned corporate director and pharmaceutical executive, and we are thrilled to welcome her to Viramal’s Board. Her commercialization expertise and broad experience across medical, clinical and regulatory affairs will be instrumental in the progression of our pipeline of highly differentiated women’s health products. Angela has a successful track record of advancing pharmaceutical companies from inception, through fundraising and commercialization, to expanding the commercial potential of products. This experience will be invaluable to Viramal as we develop innovative products that target unmet female therapeutic areas, as well as produce a step change in existing women’s healthcare products,” said William Bologna, Viramal’s Chairman.

Ms. Rossetti is currently a director at Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics, and MicroHealth, a privately held digital health network for the hemophilia community. She is an Adjunct Assistant Professor at New York Medical College. She holds a BA Biology and English from the University of Pennsylvania, an MBA Finance from Columbia University and MS Bioethics from the Albert Einstein School of Medicine/Cardozo Law School.

Viramal recently bolstered its Board of Directors with the appointment of women’s healthcare expert, William Bologna, as Chairman in February. Bill Bologna is a pioneer in women’s healthcare who has successfully developed and licensed market-leading products in fertility and female sexual health.

About Viramal

Viramal is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well-recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed and licensed Crinone®, Replens® and RepHresh®. Viramal produces a step change in these existing products, as well as develops innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety, efficacy and patient acceptability with far fewer side effects. The Company’s robust women’s health clinical development pipeline includes treatments for fertility, menopausal hormone therapy, contraception and sexual health. In addition, Viramal’s only male product, TestoCream (transdermal delivery of testosterone), has shown 81% success in a partially completed Phase III study. Please visit for more information.

Katja Buhrer
MBS Value Partners
(212) 661-7004

Leave a Reply

Your email address will not be published.